The Claim
The cerebrospinal fluid seed amplification assay for α-synuclein has a sensitivity of 96.3% and a specificity of 96.4% in detecting Lewy body pathology in individuals with Alzheimer’s disease, supporting its validation as a reliable in vivo biomarker for identifying this co-pathology in clinical and research settings.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Scientists have found a blood test-like method that can detect a specific brain problem called Lewy body pathology in people with Alzheimer’s, and it’s accurate over 96% of the time — meaning it could help doctors spot this common brain issue without needing an autopsy.
See the scientific wording
The cerebrospinal fluid seed amplification assay for α-synuclein demonstrates 96.3% sensitivity and 96.4% specificity for detecting Lewy body pathology in individuals with Alzheimer’s disease, validating its use as a reliable in vivo biomarker for identifying this common co-pathology in clinical and research settings.
What the research says
1 studyStudy: Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease
This study found that a simple spinal fluid test can accurately detect a second type of brain damage (Lewy bodies) in people with Alzheimer’s, and it works 96% of the time. This helps doctors better understand how fast someone’s memory might get worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.